Woodline Partners’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18M | Sell |
635,094
-230,831
| -27% | -$6.56M | 0.1% | 310 |
|
|
2025
Q1 | $25.6M | Buy |
865,925
+105
| +0% | +$3.1K | 0.17% | 180 |
|
|
2024
Q4 | $25.2M | Buy |
865,820
+187,666
| +28% | +$5.46M | 0.17% | 173 |
|
|
2024
Q3 | $31.1M | Buy |
678,154
+32,496
| +5% | +$1.49M | 0.26% | 125 |
|
|
2024
Q2 | $26.4M | Buy |
645,658
+59,320
| +10% | +$2.42M | 0.25% | 125 |
|
|
2024
Q1 | $15M | Buy |
586,338
+528,217
| +909% | +$13.5M | 0.14% | 203 |
|
|
2023
Q4 | $526K | Hold |
58,121
| – | – | 0.01% | 423 |
|
|
2023
Q3 | $371K | Hold |
58,121
| – | – | ﹤0.01% | 520 |
|
|
2023
Q2 | $645K | Hold |
58,121
| – | – | 0.01% | 515 |
|
|
2023
Q1 | $892K | Hold |
58,121
| – | – | 0.01% | 480 |
|
|
2022
Q4 | $1.29M | Buy |
58,121
+20,033
| +53% | +$445K | 0.02% | 520 |
|
|
2022
Q3 | $622K | Buy |
+38,088
| New | +$622K | 0.01% | 576 |
|
|
2022
Q1 | – | Sell |
-128,000
| Closed | -$3.04M | – | 805 |
|
|
2021
Q4 | $3.04M | Hold |
128,000
| – | – | 0.04% | 353 |
|
|
2021
Q3 | $3.15M | Hold |
128,000
| – | – | 0.05% | 328 |
|
|
2021
Q2 | $3.16M | Hold |
128,000
| – | – | 0.06% | 286 |
|
|
2021
Q1 | $2.79M | Hold |
128,000
| – | – | 0.06% | 251 |
|
|
2020
Q4 | $3.27M | Sell |
128,000
-44,978
| -26% | -$1.15M | 0.09% | 176 |
|
|
2020
Q3 | $4.87M | Buy |
172,978
+47,978
| +38% | +$1.35M | 0.16% | 131 |
|
|
2020
Q2 | $3.53M | Buy |
+125,000
| New | +$3.53M | 0.14% | 124 |
|